-
An Enhertu innovation map
-
Intelligence as efficient model building
-
Pharmaceutical blockbusters: the past, present, and future(?)
-
Innovation, sea snails, and the blind professor
-
Steelmanning the argument for free drug pricing
-
Where are the other Luxturna's? Challenges with gene therapy for inherited retinal diseases
-
Reasoning about response rates
-
The best ways to follow biopharma news and learn about the industry (in my opinion)
-
Ergodicity and biotech, or why expected value is a mirage
-
Developing a deeper understanding of diagnosis rates
-
Unplanned success in drug development
-
What is a good binding affinity for a drug?
- •
- 1
- 2